EBV-targeted cell therapy for EBV-related lymph disorders
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your cancer or lymph disorder must be linked to the Epstein-Barr virus (EBV) and have not improved after standard treatment or you cannot have standard treatment.
- You must have one of these immune system types (HLA types): A02:01, A11:01, or A24:02.
- You must be able to care for yourself (Karnofsky score of 70 or more) and have a life expectancy of at least 3 months.
- You must not have serious heart disease, uncontrolled infections, or other active cancers in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new Epstein-Barr Virus-Associated Lymphoproliferative Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.